UPA Dual-Pathway Metabolic Research Pen - Tirzepatide (Tidlira 30) 30 mg Total | Prefilled Pen
R 2,300.00 ZAR
Skip to product information
UPA Dual-Pathway Metabolic Research Pen - Tirzepatide (Tidlira 30) 30 mg Total | Prefilled Pen
R 2,300.00 ZAR
Product Overview
Tidlira 30 is a Tirzepatide-based compound supplied in a prefilled pen format. Tirzepatide is a synthetic peptide compound commonly referenced in research environments for its interaction with multiple receptor signalling pathways associated with metabolic regulation.
This pen-based format offers a controlled, pre-measured delivery system intended for users familiar with peptide pen handling and compound protocols.
Compound Information
Tirzepatide compound
Dual-pathway signalling interaction profile
Supplied in a prefilled pen format
Precision dial-based delivery mechanism
Format Information
Prefilled Pen Format
This product is supplied as a ready-to-use pen containing a measured quantity of compound. Designed for convenience, consistency, and controlled dispensing.
General Research Context
Tirzepatide has been widely referenced in scientific literature exploring metabolic signalling pathways, receptor interaction models, and regulatory system frameworks.
No claims are made regarding appetite modulation, weight management, glucose control, insulin response, or therapeutic outcomes.
Storage & Handling
Store according to packaging instructions
Refrigeration recommended unless otherwise specified
Do not use if the solution appears cloudy or contains visible particles
Handle using appropriate compound protocols
Intended Audience
This product is intended for experienced users familiar with peptide-based compounds and pen-format handling systems.
Disclaimer
This product is not intended to diagnose, treat, cure, or prevent any disease.
Additional Disclaimer
All compound products are supplied for catalogue and informational purposes only. Customers are responsible for ensuring appropriate handling, preparation, and compliance with applicable regulations.